PMID- 28746469
OWN - NLM
STAT- MEDLINE
DCOM- 20171204
LR  - 20181202
IS  - 1414-431X (Electronic)
IS  - 0100-879X (Print)
IS  - 0100-879X (Linking)
VI  - 50
IP  - 8
DP  - 2017 Jul 20
TI  - Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer 
      cells.
PG  - e6207
LID - S0100-879X2017000800610 [pii]
LID - 10.1590/1414-431X20176207 [doi]
LID - e6207
AB  - Both sorafenib and interleukin-27 (IL-27) are antineoplastic drugs. This study 
      aimed to investigate the synergistic effect of these two drugs on bladder cancer 
      cells. HTB-9 and T24 cells were stimulated with IL-27 (50 ng/mL), sorafenib (2 
      muM) or the synergistic action of these two drugs. The cells without treatment 
      acted as control. Cell proliferation, apoptosis and invasion were measured by 
      bromodeoxyuridine assay, flow cytometry and modified Boyden chamber, 
      respectively. Simultaneously, both modified Boyden chamber and scratch assay were 
      used to assess cell migration. Finally, the phosphorylation levels of key kinases 
      in the Akt/mechanistic target of rapamycin (mTOR)/mitogen-activated protein 
      kinase (MAPK) pathway, and expression levels of matrix metalloproteinase (MMP)-2 
      and MMP-9 were detected by western blot analysis. Stimulation with IL-27 or 
      sorafenib repressed proliferation, migration and invasion but promoted apoptosis, 
      and the effects were all enhanced by the combination of these two drugs in HTB-9 
      cells. The effect of the combined treatment on bladder cancer cells was verified 
      in T24 cells. Additionally, the phosphorylation levels of AKT, mTOR and MAPK as 
      well as the expression levels of MMP-2 and MMP-9 were all decreased by a single 
      treatment of IL-27 or sorafenib, and further decreased by the combined treatment 
      of these two drugs. The combination of IL-27 and sorafenib inhibited 
      proliferation, migration and invasion and promoted apoptosis of bladder cancer 
      cells compared with mono-drug treatment. Additionally, the AKT/mTOR/MAPK pathway 
      might be implicated in the functional effects by down-regulations of MMP-2 and 
      MMP-9.
FAU - Cao, J Y
AU  - Cao JY
AD  - Department of Urology, Binzhou Medical University Hospital, Binzhou, China.
FAU - Yin, H S
AU  - Yin HS
AD  - Department of Urology, Binzhou Medical University Hospital, Binzhou, China.
FAU - Li, H S
AU  - Li HS
AD  - Department of Gastrointestinal Surgery, Binzhou Medical University Hospital, 
      Binzhou, China.
FAU - Yu, X Q
AU  - Yu XQ
AD  - Department of Gastrointestinal Surgery, Binzhou Medical University Hospital, 
      Binzhou, China.
FAU - Han, X
AU  - Han X
AD  - Department of Gastrointestinal Surgery, Binzhou Medical University Hospital, 
      Binzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20170720
PL  - Brazil
TA  - Braz J Med Biol Res
JT  - Brazilian journal of medical and biological research = Revista brasileira de 
      pesquisas medicas e biologicas
JID - 8112917
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interleukin-27)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/drug effects
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Drug Synergism
MH  - Humans
MH  - Interleukin-27/*pharmacology
MH  - Niacinamide/*analogs & derivatives/pharmacology
MH  - Phenylurea Compounds/*pharmacology
MH  - Sorafenib
MH  - Urinary Bladder Neoplasms/drug therapy/*pathology
PMC - PMC5520222
EDAT- 2017/07/27 06:00
MHDA- 2017/12/05 06:00
PMCR- 2017/07/17
CRDT- 2017/07/27 06:00
PHST- 2017/01/25 00:00 [received]
PHST- 2017/05/22 00:00 [accepted]
PHST- 2017/07/27 06:00 [entrez]
PHST- 2017/07/27 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2017/07/17 00:00 [pmc-release]
AID - S0100-879X2017000800610 [pii]
AID - 10.1590/1414-431X20176207 [doi]
PST - epublish
SO  - Braz J Med Biol Res. 2017 Jul 20;50(8):e6207. doi: 10.1590/1414-431X20176207.